AI Airlock Phase 2 Cohort

AI Summary

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has initiated Phase 2 of the AI Airlock program, involving companies such as TORTUS, Numan, Panakeia Technologies, Octopath, NHS England, Eye2Gene Ltd, and DeepX Health. This phase is scheduled to run until April 2026, with individual project testing lasting approximately six months. The initiative addresses critical regulatory challenges under the UK Medical Device Regulations, specifically the lack of established benchmarks for AI-driven clinical documentation, diagnostics, and decision-support tools. Key issues include defining the boundaries of intended use to prevent unauthorized reclassification from Class I to Class IIa, validating direct-to-patient AI explanations, and managing performance drift in adaptive diagnostic systems. To address these hurdles, participating companies are required to conduct rigorous testing across simulation, virtual, and real-world environments. They must generate evidence for safety and effectiveness, fund their own data access, and co-develop Predetermined Change Control Plans (PCCPs) with regulators. These actions aim to establish standardized post-market surveillance and clearer validation pathways, ensuring that AI-based medical devices meet safety requirements while allowing for responsible technological evolution within the UK healthcare landscape.